BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12945944)

  • 1. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas.
    Hentschel SJ; McCutcheon lE; Moore W; Durity FA
    Can J Neurol Sci; 2003 Aug; 30(3):215-9. PubMed ID: 12945944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
    Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
    Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas].
    Miyagami M; Nakamura S
    No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric DNA ploidy and cells phase fractions in recurrent human pituitary adenomas. A correlative study of flow cytometric analysis and the expression of proliferating cell nuclear antigen.
    Chae YS; Flotte T; Hsu DW; Preffer F; Hedley-Whyte ET
    Gen Diagn Pathol; 1996 Oct; 142(2):89-95. PubMed ID: 8950573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
    Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
    Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mdm2 and the p53 pathway in human pituitary adenomas.
    Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
    Saeger W; Lüdecke B; Lüdecke DK
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
    Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
    Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas.
    Sarkar S; Philip VJ; Cherukuri SK; Chacko AG; Chacko G
    Acta Neurochir (Wien); 2017 Nov; 159(11):2179-2186. PubMed ID: 28573325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathobiology of pituitary adenomas and carcinomas.
    Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
    Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
    Matsuyama J
    Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas.
    Fukui S; Otani N; Nawashiro H; Yano A; Nomura N; Miyazawa T; Ohnuki A; Tsuzuki N; Katoh H; Ishihara S; Shima K
    Brain Tumor Pathol; 2002; 19(1):23-9. PubMed ID: 12455885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation markers in different types of clinically non-secreting pituitary adenomas.
    Schreiber S; Saeger W; Lüdecke DK
    Pituitary; 1999 May; 1(3-4):213-20. PubMed ID: 11081200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence in pituitary adenomas in childhood and adolescence.
    Espay AJ; Azzarelli B; Williams LS; Bodensteiner JB
    J Child Neurol; 2001 May; 16(5):364-7. PubMed ID: 11392522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and growth fractions of pituitary adenomas.
    Yonezawa K; Tamaki N; Kokunai T
    Surg Neurol; 1997 Nov; 48(5):494-500. PubMed ID: 9352815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
    Abramovich CM; Prayson RA
    Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plurihormonality of pituitary adenomas in light of immunohistochemical studies.
    Pawlikowski M; Kunert-Radek J; Radek M
    Endokrynol Pol; 2010; 61(1):63-6. PubMed ID: 20205106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
    Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
    Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrences of Pituitary Adenomas or Second De Novo Tumors: Comparisons with First Tumors.
    Saeger W; Müller M; Buslei R; Flitsch J; Fahlbusch R; Buchfelder M; Knappe UJ; Crock PA; Lüdecke DK
    World Neurosurg; 2018 Nov; 119():e118-e124. PubMed ID: 30026158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
    Lath R; Chacko G; Chandy MJ
    Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.